Page 2 - Weight Loss

Russian teens turn to Molecule, a banned pill with deadly weight-loss risks

Marketed as a herbal weight-loss supplement, Molecule has gone viral on Russian TikTok but contains a banned drug linked to heart attacks, anxiety, and hospitalisations among teenagers

Weight-gain woes after the festive cheer? Here's how to bounce-back

From balanced home meals to fun, everyday activities, here's how you can ease back into fitness and lose festive weight sustainably.

New study links weight loss drugs to better liver health outcomes

A new review highlights how anti-obesity drugs like semaglutide and tirzepatide may help reverse fat build-up, inflammation, and scarring in patients with MASLD and MASH

India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges

Novo Nordisk's Ozempic launch adds to its GLP-1 portfolio, offering patients new options while competing with Eli Lilly's Mounjaro in India

'Fat but fit': New study finds being underweight deadlier than overweight

Those at the lower end of the "healthy" range also faced higher risks, with BMIs between 18.5 and 19.9 doubling the likelihood of death

After Mounjaro success, Eli Lilly plans to launch weight-loss pill in India

Unlike injectable Mounjaro, which focuses on patients with a BMI above 35, Orforglipron is designed for the larger group of patients with a BMI of 27-34, offering an expected weight reduction of 12-16

Are superfoods really healthy? Doctors bust popular wellness myths

Superfoods may boost your diet, but they are no cure-alls. Doctors explain why balance, variety, and local produce matter more than chasing the latest wellness fads

Semaglutide, used in Ozempic, joins WHO's essential medicines list

From cancer drugs to diabetes therapies, WHO's new list expands access to modern medicines and boosts the push for global healthcare equity

Scientists test 4-in-1 drug that may rival Ozempic and bariatric surgery

Researchers explore next-gen obesity drug targeting four hormones at once to overcome limits of existing treatments

Will this court fight make the world's hottest weight-loss drug cheaper?

Indian pharma takes Novo Nordisk to court over patents that keep Wegovy and Ozempic out of reach - could this slash prices for millions of patients?

From stomach paralysis to vision loss: Ozempic faces over $2 bn lawsuits

Ozempic, the viral weight-loss injection, is now in the dock with $2 billion lawsuits as patients allege stomach paralysis, vision loss, and lasting health damage

Eli Lilly to raise UK price of weight-loss drug Mounjaro by 170%

The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September

Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets diabetes and obesity, competing with Wegovy

Ozempic, other weight-loss drugs tied to rare, serious eye issue: Study

Non-arteritic anterior ischaemic optic neuropathy, or NAION, is a rare but devastating eye condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked

Cult Fit co-founder's realistic weight loss lessons for lasting results

From better sleep to mindful hydration, Cult Fit co-founder Rishabh Telang shares six simple, science-backed weight loss tips that fit into real life, no crash diets required

How Ozempic maker Novo Nordisk lost sheen after creating wonder drug

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes

Weighty issues: India's rush to make weight-loss drugs demands user caution

The global market for weight-loss drugs is estimated at $100 billion by the end of the decade

Ozempic maker's plight shows why managing markets matter for pharma giants

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting market sentiment in high-growth pharma bets

CDMOs gear up for peptide boom amid rising demand for weight-loss drugs

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent expiries such as that of semaglutide in 2026

Ozempic to Mounjaro: India’s in a full-blown weight-loss drug war | Wegovy | Belly-fat | Health drug

India’s weight-loss game is getting serious! The country’s anti-obesity market is now worth ₹628 crore, and it’s climbing fast! Watch this video for a quick look at the top contenders